Tertiary Lymphoid Structures Predict Prognosis and Immune Checkpoint Inhibitor Efficacy in Lung Squamous Cell Carcinoma
Immunology · 2026-01 · 177 (1) · 109-118
DOI: 10.1111/imm.70027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, online erschienen am 15.08.2025. Verfasst von Kuifei Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Taizhou Hospital of Zhejiang Province, Shaoxing University, Taizhou, Zhejiang, China. Hauptthemen laut MEDLINE: Tertiary Lymphoid Structures, Lung Neoplasms, Immune Checkpoint Inhibitors, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Basic Public Welfare Research Project of Zhejiang Province, Medicine and Health Science and Technology Project of Zhejiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Lung squamous cell carcinoma (LUSC) is a highly mortal cancer. Tertiary lymphoid structures (TLSs) play a crucial role in creating a specific and essential environment for the development of cellular and humoral immune responses against tumours. This study investigated the effect of TLSs on prognosis and the prediction of immunotherapy efficacy in LUSC. To investigate the association between TLSs and clinicopathological features, haematoxylin and eosin staining and multiple immunofluorescence staining were performed. A comparative examination of survival and the factors influencing it was carried out between the TLS−/+, high and low TLS density, immature tertiary lymphoid structures (imTLS) and mature tertiary lymphoid structures (mTLS) groups of patients. To further analyse the prognostic value of TLSs in the immunotherapy cohort of patients with LUSC, two hundred and ninety‐seven patients with LUSC were enrolled in this study. Of these, 129 patients were harbouring TLS+. Cramer's V relationships analysis revealed that both Stage ( p = 0.029) and PD‐L1 ≥ 50% ( p = 0.011) were significant predictors of TLS+. Cox proportional hazards model multivariate analysis showed that the TLS+ ( p = 0.037), high TLS density ( p = 0.014) and mTLS ( p = 0.001) were associated with better overall survival (OS) in LUSC patients. Multivariate analyses confirmed that TLS+ was an independent prognostic predictor for OS in the LUSC immunotherapy cohort ( p = 0.021). This study provided evidence that LUSC patients with TLS+, high TLS density and mTLS had a favourable prognosis, suggesting that TLSs are an independent positive prognostic factor for LUSC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Taizhou Hospital of Zhejiang Province, Shaoxing University, Taizhou, Zhejiang, China.
- Key Laboratory of Radiation Oncology of Taizhou, Radiation Oncology Institute of Enze Medical Health Academy, Department of Radiation Oncology, Taizhou Hospital Affiliated to Wenzhou Medical University, Taizhou, Zhejian…
- Department of Pathology, Taizhou Hospital Affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
ORCID-Profile: Haihua Yang
Förderung
- Basic Public Welfare Research Project of Zhejiang Province
- Medicine and Health Science and Technology Project of Zhejiang Province
- National Natural Science Foundation of China
Zitieren
APA
Chen, K., Zhou, S., Zhou, P., Sun, Z., Xu, Y., Chen, Z., Zhang, L., Pi, W., Gan, M., & Yang, H. (2026). Tertiary Lymphoid Structures Predict Prognosis and Immune Checkpoint Inhibitor Efficacy in Lung Squamous Cell Carcinoma. Immunology, 177(1), 109-118. https://doi.org/10.1111/imm.70027
Vancouver
Chen K, Zhou S, Zhou P, Sun Z, Xu Y, Chen Z, et al. Tertiary Lymphoid Structures Predict Prognosis and Immune Checkpoint Inhibitor Efficacy in Lung Squamous Cell Carcinoma. Immunology. 2026;177(1):109-118. doi:10.1111/imm.70027
BibTeX
@article{Chen2026,
author = {Chen, Kuifei and Zhou, Suna and Zhou, Pin and Sun, Zhenwei and Xu, Yixiu and Chen, Ziran and Zhang, Liangmin and Pi, Wenhu and Gan, Meifu and Yang, Haihua},
title = {Tertiary Lymphoid Structures Predict Prognosis and Immune Checkpoint Inhibitor Efficacy in Lung Squamous Cell Carcinoma},
journal = {Immunology},
year = {2026},
volume = {177},
number = {1},
pages = {109--118},
doi = {10.1111/imm.70027}
}
EUVIMED